CNMD CONMED Corp

CNMD financial statements, revenue, balance sheet, cash flow, and SEC filings

CIK: 816956 Exchange: NYSE SIC: 3845 (Electromedical & Electrotherapeutic Apparatus) Latest filing: 10-Q filed Jul 29, 2026 Data checked: Oct 21, 2026
Showing 3 of 17 annual and 0 of 63 quarterly periods. Full history available with a free account or via API.

▼ Company Profile

Filer Category
Large accelerated filer
Entity Type
Operating
Public Float
$1.20B (Jun 2025)
Industry (SIC)
3845 Electromedical & Electrotherapeutic Apparatus
Incorporated
DE
Fiscal Year End
December (1231)
Phone
727-214-2974
EIN
160977505
Headquarters
LARGO, FL, 33773
Public Float History
Market value of shares held by public investors, reported in annual DEI filings.

▼ Key Metrics (TTM)

As of Dec 31, 2025
Financials
Revenue
$1.37B
Net Income
$47.06M
Total Assets
$2.33B
Total Equity
$1.03B
Total Debt
-
Free Cash Flow
$150.88M
Ratios
Gross Margin
54.6%
Operating Margin
7.5%
Net Margin
3.4%
Return on Equity
4.6%
Return on Assets
2%
Current Ratio
2.14x
FCF / Assets
6.5%

▼ FY 2025 Summary Analysis

Annual report ending Dec 31, 2025

Overview and Growth

In fiscal 2025, CONMED Corp recorded $1.37B of revenue, net income of $47.05M, and an operating cash inflow of $170.69M. Revenue of $1.37B sets the scale for evaluating how effectively sales translated into profit and cash during the year. Revenue was 5.2% above fiscal 2024 revenue of $1.31B, marking a year-over-year increase. On a per-share basis, diluted EPS was $1.51, which connects the reported earnings outcome with the company’s diluted share count. The per-share result recorded a 64.5% decrease from fiscal 2024 diluted EPS of $4.25. The revenue-to-assets relationship was 0.59x, showing the sales generated relative to the resources carried on the balance sheet.

Profitability

Gross profit was $750.48M, representing the portion of revenue remaining after the reported cost of revenue and before operating expenses. The gross-profit relationship equaled 54.6% of revenue, quantifying the portion retained before operating expenses were recognized. Operations produced $102.62M of income after the reported operating expense base, before the remaining non-operating and tax effects. Relative to revenue, operating income represented 7.5%, showing how efficiently sales converted into operating profit. Net income came to $47.05M, completing the progression from revenue through gross and operating profitability to the final reported result. Measured against reported revenue, net income produced a 3.4% margin after operating costs and the remaining recognized items. The earnings statement records $71.12M of pretax income, the profit base against which the reported tax provision can be assessed. Pretax income represented 5.2% of revenue, placing earnings before tax in the context of the company’s operating scale. The company recognized $24.06M of income tax for the period, completing the transition from pretax income to net income. Relative to pretax income, the tax provision measured 33.8%, quantifying the portion of pre-tax earnings paid in income tax. Net income equaled 4.6% of period-end equity, showing the earnings generated on shareholders’ book capital. Net income represented 2.0% of period-end assets, placing the company’s bottom-line result against the total resource base employed.

Liquidity and Capital Structure

Total assets were $2.33B, supported by $1.29B of liabilities and $1.03B of shareholder equity. At period end, current assets of $672.86M compared with current liabilities of $315.04M, defining the company’s short-term resource position. Current assets covered current liabilities by 2.14x, leaving a positive buffer for near-term obligations. Reported cash and equivalents were $40.82M, separating immediately recognizable cash resources from the rest of the current-asset base. Measured only with cash and equivalents, coverage of current liabilities was 13.0%, excluding receivables and other current assets. Liabilities represented 55.6% of total assets, quantifying the liability-funded share of the company’s resource base. Cash and equivalents equaled 1.8% of total assets, showing the liquid cash component within the company’s broader resource base. Compared with $2.31B in fiscal 2024, the current asset base moved 0.8% and finished higher.

Cash Flow and Earnings Quality

Operating activities produced a cash inflow of $170.69M, giving the cash-flow counterpart to the accrual-based profit measures reported for the year. Against net income, operating cash flow measured 3.63x, showing the relationship between accrual earnings and operating cash. Capital expenditures used $19.81M, identifying the reported investment outflow deducted from operating cash flow in the free-cash-flow calculation. Capital expenditures represented 11.6% of operating cash flow, leaving the remainder available as free cash flow. After capital spending, free cash flow was $150.88M, leaving cash available for debt reduction, shareholder returns, or further investment. The free-cash-flow margin was 11.0%, measuring cash remaining after capital spending against revenue. Free cash flow equaled 6.5% of total assets, relating post-investment cash generation to the company’s resource base.
Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated .
Sources and calculation details

Reported values are preserved. Derived values use the listed inputs; unavailable inputs remain blank.

Field-level sources for this historical record are unavailable until it is rebuilt from SEC facts.

Annual financial statements for CONMED Corp
Metric FY2025 📄 FY2024 📄 FY2023 📄
Income Statement
REVENUE
Revenue $1.37B $1.31B $1.24B
Cost of Revenue $624.25M $573.98M $568.50M
Gross Profit $750.48M $733.03M $676.25M
OPERATING EXPENSES
R&D Expense $55.88M $54.43M $52.60M
SG&A Expense $591.97M $478.28M $503.04M
Other Operating Expenses (derived) $0 $0 $0
Operating Income $102.62M $200.33M $120.60M
NON-OPERATING INCOME / EXPENSE
Interest Expense $31.09M $37.30M $39.78M
Pretax Income $71.12M $163.03M $80.83M
Income Tax $24.06M $30.61M $16.37M
Net Income $47.06M $132.42M $64.46M
PER SHARE & SUPPLEMENTAL
Diluted EPS $1.51 $4.25 $2.04
Diluted Shares 31.15M 31.15M 31.55M
EBITDA $119.77M $216.93M $136.80M
Depreciation & Amortization $17.14M $16.61M $16.20M
Balance Sheet
ASSETS
Cash & Equivalents $40.82M $24.46M $24.30M
Accounts Receivable $247.83M $237.73M $242.28M
Inventory $355.54M $346.72M $318.32M
Other Current Assets $28.67M $31.10M $30.75M
Current Assets $672.86M $640.01M $615.65M
PP&E (Net) $113.33M $115.79M $120.72M
Goodwill $807.01M $805.36M $806.84M
Intangible Assets $582.05M $617.66M $649.48M
Other Noncurrent Assets $137.19M $116.36M $96.11M
Noncurrent Assets $1.65B $1.67B $1.68B
Total Assets $2.33B $2.31B $2.30B
LIABILITIES
Accounts Payable $93.65M $102.25M $88.22M
Other Current Liabilities $138.54M $109.80M $151.73M
Current Liabilities $315.04M $278.13M $310.73M
Other Noncurrent Liabilities $63.85M $86.29M $121.03M
Noncurrent Liabilities $977.61M $1.07B $1.16B
Total Liabilities $1.29B $1.34B $1.47B
EQUITY
Common Stock $313.00K $313.00K $313.00K
Additional Paid-in Capital $503.20M $476.58M $446.54M
Retained Earnings $588.77M $560.28M $452.53M
Accumulated OCI $-46.30M $-58.86M $-50.17M
Total Equity $1.03B $962.68M $834.22M
Total Liabilities & Equity $2.33B $2.31B $2.30B
SUPPLEMENTAL
Check: A − (L + E + Temp. Equity) - - -
Cash Flow Statement
Cash from Operations $170.69M $166.97M $125.35M
Capital Expenditures $19.81M $13.08M $19.03M
Cash from Investing $-20.96M $-13.08M $-20.03M
Cash from Financing $-135.82M $-151.00M $-110.43M
Free Cash Flow $150.88M $153.88M $106.32M
Beginning Cash (CFS) $24.46M $24.30M $28.94M
Net Change in Cash $13.91M $2.88M $-5.12M
Effect of FX on Cash $2.45M $-2.72M $470.00K
Calculated Ending Cash $40.82M $24.46M $24.30M
Cash per BS $40.82M $24.46M $24.30M
Cash scope difference (CFS − BS) - - -
Cash per CFS $40.82M $24.46M $24.30M

Create a free account to see full history, quarterly data, charts, CSV downloads, and API access.

Create Free Account Log In
🔒

Quarterly data and charts require a free account

Get access to 8 quarters of data, interactive charts, CSV downloads, and API access.

▼ Frequently Asked Questions

What is CONMED Corp's annual revenue?

CONMED Corp reported $1.37B in revenue for trailing twelve months (ending December 2025). Revenue figures are sourced from the company's annual SEC EDGAR filing.

Is CONMED Corp profitable?

Yes. CONMED Corp reported $47.06M in net income for trailing twelve months. Profitability data is based on the company's most recent annual report filed with the SEC.

Does CONMED Corp generate free cash flow?

Yes. Free cash flow was $150.88M for trailing twelve months. Operating cash flow was $170.69M.